Kim SH, Han SY, Azam T, Yoon DY, Dinarello C (2005) Interleukin-32: A cytokine and inducer of TNFα. Immunity 22: 131–142.
[2]
Beutler B, Jiang Z, Georgel G, Krozat K, Croker B (2006) Genetic analysis of host resistance: Toll-like receptor signalling and immunity at large. Annu Rev Immunol 24: 353–389. et al.
[3]
Inohara C, McDonald C, Nunez G (2005) NOD-LRR proteins: Role in host-microbial interactions and inflammatory disease. Annu Rev Biochem 74: 355–383.
[4]
Netea MG, Azam T, Ferwerda G, Giardin SE, Walsh M (2005) IL-32 synergizes with nucleotide oligomerization domain (NOD) and NOD2 ligands for IL-1？ and IL-6 production through a caspase 1-dependent mechanism. Proc Natl Acad Sci 32: 16309–16314. et al.
[5]
Ferwerda G, Girardin SE, Kulberg B, le Bourhis L, de Jong DJ (2005) NOD2 and Toll-like receptors are nonredundant recognition systems of Mycobacterium tuberculosis. PLoS Path 1: 279–285. DOI: 10.1371/journal.ppat.0010034.
[6]
Netea MG, Azam T, Lewis EC, Joosten LAB, Wang M (2006) Mycobacterium tuberculosis induces interleukin-32 production through a caspase-1/IL-18/interferon-γ dependent mechanism. PLoS Med 3: In press.
[7]
Doffinger R, Dupuis S, Picard C, Fieschi C, Feinberg J (2002) Inherited disorders of IL-12- and IFNγ-mediated immunity: A molecular genetics update. Mol Immunol 38: 903–909. et al.
[8]
Novick D, Rubinstein M, Azam T, Rabinov A, Dinarello CA (2006) Proteinase 3 is an IL-32 binding protein. Proc Natl Acad Sci 103: 3316–3321. et al.
[9]
Sun D, Ding A (2006) MyD88-mediated stabilization of interferon-γ-induced cytokine and chemokine mRNA. Nat Immunol 7: 375–381.
[10]
Fremond CM, Yeremeev V, Nicolle DM, Jacobs M, Quesniaux VF (2004) Fatal Mycobacterium tuberculosis infection despite adaptive immune response in the absence of MyD88. J Clin Invest 114: 1790–1799. et al.
[11]
Mazumder B, Seshadri V, Fox PL (2003) Translational control by the 3′-UTR: The ends specify the means. Trends Biochem Sci 28: 91–98.
[12]
Joosten LA, Netea MG, Kim SH, Yoon DY, Oppers-Walgreen B (2006) IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci 103: 3298–3303. et al.
[13]
Mayordomo L, Marenco JL, Gomez-Mateos J, Rejon E (2002) Pulmonary miliary tuberculosis in a patient with anti-TNF-alpha treatment. Scand J Rheumatol 31: 44–45.
